Search

Your search keyword '"van Leeuwen, L."' showing total 480 results
Start Over Author "van Leeuwen, L."
480 results on '"van Leeuwen, L."'

3. MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Author

van Leeuwen-Stok, E., van Leeuwen, L., de Graaf, H., van Riel, J.M.G.H., Houtsma, D., Vrijaldenhoven, S., van der Velden, A.W.G., Peerdeman, A.L., van den Brink - Schimmel, R.J., Drooger, J.C., Imholz, A.L.Th., Dercksen, M.W., Oulad Hadj, J., Bakker, S.D., van der Wouw, A.J., Kerver, E.D., Bouma, G., van Schaik, C., de Boer, M., Mandigers, C.M.P.W., Koornstra, R.H.T., Smals, A., Rietbroek, R.C., van der Padt - Pruijsten, A., den Boer, M.O., Bos, H., Schiphorst, P.P.J.B.M., Vriens, B.E.P.J., van Rossum, Q.C., Tol, J., Hoogwerf - Kluft, D., Kruijtzer - Schimmel, C.M.F., Oosterkamp, H.M., Baas, I.O., Dietvorst, A.H.P., Davidis - van Schoonhoven, M., van Dijk, M.A., van der Voort, Anna, Louis, Fleur M, van Ramshorst, Mette S, Kessels, Rob, Mandjes, Ingrid A, Kemper, Inge, Agterof, Mariette J, van der Steeg, Wim A, Heijns, Joan B, van Bekkum, Marlies L, Siemerink, Ester J, Kuijer, Philomeen M, Scholten, Astrid, Wesseling, Jelle, Vrancken Peeters, Marie-Jeanne T F D, Mann, Ritse M, and Sonke, Gabe S

Published
2024
Full Text
View/download PDF

6. Impact of device variability and protocol differences on kidney function during normothermic machine perfusion: A comparative study using porcine and human kidneys.

Author

Lantinga, Veerle A., Arykbaeva, Asel S., Spraakman, Nora A., Blom, Elwin W. P., Huijink, Tobias M., de Vries, Dorottya K., Ploeg, Rutger J., Alwayn, Ian P. J., Leuvenink, Henri G. D., Moers, Cyril, and van Leeuwen, L. Leonie

Subjects
VASCULAR resistance, KIDNEY physiology, KIDNEY transplantation, COLD storage, CHARACTERISTIC functions, PERFUSION, OXYGEN consumption
Abstract

Introduction: A growing interest in renal normothermic machine perfusion (NMP) has resulted in more clinically available perfusion devices. While all perfusion systems have the same aim, there are significant differences in their circuits, pumps, sensors, and software. Therefore, our objective was to assess the impact of different perfusion protocols and devices on kidney function and perfusion parameters during NMP. Methods: Porcine kidneys were subjected to 30 min of warm ischemia, 24 h of static cold storage, and subsequently perfused for 6 h using (1) the Kidney Assist (KA) machine with a pressure of 75 mm Hg, (2) the KA device incorporating several adjustments and a pressure of 85 mm Hg (modified KA), or (3) the Perlife (PL) perfusion device (n = 4). Consecutively, discarded human kidneys were perfused using the KA or modified KA (n = 3) protocol. Results: The PL group quickly reached the device's upper flow limit and consequently received a significantly lower pressure compared to the KA groups. The arterial pO2 was significantly lower in the PL group. Yet, hemoglobin concentration increased over time, and oxygen consumption was significantly higher compared to the KA groups. Fractional sodium excretion was significantly lower in the PL group. Tissue ATP levels, urine production, and creatinine clearance rates did not differ between groups. In human kidneys, the modified KA group showed significantly lower vascular resistance, higher oxygen delivery, and lower levels of lactate in the perfusate compared to the KA group. Conclusions: This study shows that perfusion characteristics and kidney function are significantly influenced by the perfusion protocol and the device and its settings during normothermic machine perfusion and therefore should be interpreted with caution. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

7. Unlocking the Promise of Liver Perfusion Technologies for Pediatric Transplantation: A State‐of‐the‐Art Review.

Author

Brown, Cole S., van Leeuwen, L. Leonie, Akhtar, M. Zeeshan, and DiNorcia, Joseph

Subjects
*LIVER transplantation, *CHILD patients, *GROUP work in education, *CHILD mortality, *PERFUSION
Abstract

Background: Outcomes after pediatric liver transplantation are generally excellent, but the limited avavailability of suitable, size‐matched liver allografts remains a significant barrier. Machine perfusion technology has emerged as a promising approach to expand the donor pool, enabling the use of less ideal whole liver grafts, such as livers donated after circulatory death, and enhancing the execution of split liver transplantation. Methods: This review examines the application of machine perfusion in pediatric liver transplantation, focusing on two primary techniques: hypothermic oxygentaed perfusion and normothermic machine perfusion. These methods optimize storage, resuscitation, and assessment of liver grafts before transplantation, potentially expanding the range of usable donor organs. Results: The use of machine perfusion allows for the consideration of suboptimal donor livers and facilitates split liver transplantation, both of which could increase organ availability for pediatric patients. Implementation of machine perfusion could also help reduce waiting list mortality by enabling the safe use of a broader spectrum of donor organs. Conclusions: Adoption of machine perfusion in pediatric liver transplantation will require collaborative, multidisciplinary efforts across transplant centers. By fostering cooperative learning and sharing resources. the integration of machine perfusion into clinical practice has the potential to reduce mortality among children awaiting liver transplantation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. The association between hemoglobin levels and renal function parameters during normothermic machine perfusion: A retrospective cohort study using porcine kidneys.

Author

van Furth, L. Annick, Huijink, Tobias M., van Leeuwen, L. Leonie, Maassen, Hanno, Lantinga, Veerle A., Ogurlu, Baran, Hamelink, Tim L., Pool, Merel B. F., Schutter, Rianne, Veldhuis, Susanne Z. J., Ottens, Petra J., Moers, Cyril, Berger, Stefan. P., Leuvenink, Henri G. D., Posma, Rene A., and Venema, Leonie H.

Subjects
KIDNEY physiology, KIDNEY transplantation, HEMOGLOBINS, LABORATORY animals, EXCRETION
Abstract

Background: Ex vivo normothermic machine perfusion (NMP) is a promising tool for assessing an isolated kidney prior to transplantation. However, there is no consensus on the perfusate's optimal oxygen‐carrying capacity to support renal function. To investigate the association of hemoglobin levels with renal function parameters, a retrospective analysis of isolated, normothermically, perfused porcine kidneys was performed. Methods: Between 2015 and 2021, a total of 228 kidneys underwent 4 h of NMP with perfusates that varied in hemoglobin levels. A generalized linear model was used to determine the association of hemoglobin levels with time‐weighted means of renal function markers, such as fractional sodium excretion (FENa) and creatinine clearance (CrCl). Stratified by baseline hemoglobin level (<4.5, 4.5–6, or >6 mmol/L), these markers were modeled over time using a generalized linear mixed‐effects model. All models were adjusted for potential confounders. Results: Until a hemoglobin level of around 5 mmol/L was reached, increasing hemoglobin levels were associated with superior FENa and CrCl. Thereafter, this association plateaued. When hemoglobin levels were categorized, hemoglobin <4.5 mmol/L was associated with worse renal function. Hemoglobin levels were neither significantly associated with proteinuria during NMP nor with ATP levels at the end of NMP. Hemoglobin levels >6 mmol/L showed no additional benefits in renal function. Conclusion: In conclusion, we found an association between baseline hemoglobin levels and superior renal function parameters, but not injury, during NMP of porcine kidneys. Furthermore, we show that performing a retrospective cohort study of preclinical data is feasible and able to answer additional questions, reducing the potential use of laboratory animals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

van Loenhout, C.J., van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, B.E.E.M., van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P., Libourel, E.J., Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C., Heller, R., de Groot, J.W.B., Stigt, J.A., Nuij, V.J.A.A., Pitz, C.C.M., Slingerland, M., Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C. van 't, Aarts, M.J.B., van Putten, J.W.G., Youssef, M., Cirkel, G.A., Herder, G.J.M., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H.T., Claessens, N.J.M., Faber, L.M., Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H., Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M., van Lindert, A.S.R., van de Wouw, A.J., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., Bootsma, G.P., de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne-Marie C., and van der Veldt, Astrid A.M.

Published
2020
Full Text
View/download PDF

13. Cumulatie ZZS en vergunningverlening (vervolgonderzoek 2023)

Author

Bodar, CWM, ter Burg, W, Faber, M, van Herwijnen, R, Hof, M, van Leeuwen, L, Naus, M, Pronk, M, Bodar, CWM, ter Burg, W, Faber, M, van Herwijnen, R, Hof, M, van Leeuwen, L, Naus, M, and Pronk, M

Abstract

RIVM rapport:Bedrijven krijgen van de overheid een vergunning voor de hoeveelheid chemische stoffen, waaronder Zeer Zorgwekkende Stoffen (ZZS(Zeer Zorgwekkende Stoffen)), die ze mogen uitstoten. De industrie stoot vaak mengsels van verschillende stoffen tegelijk uit naar water en lucht, maar de vergunningverlener beoordeelt meestal de risico’s per stof en niet van het hele mengsel. Mensen en het milieu kunnen aan zulke mengsels worden blootgesteld. De schadelijke effecten van een mengsel kunnen groter zijn dan de effecten van één stof (cumulatie). Hoe groot die kans is, hangt af van de samenstelling, de concentraties en de schadelijkheid van de stoffen. In een eerder onderzoek heeft het RIVM verkend welke mogelijkheden er zijn om bij de vergunningverlening meer rekening te houden met het effect van een mengsel. Die mogelijkheden zijn nu verder uitgewerkt. Het RIVM heeft onder andere methoden ontwikkeld om de effecten van stoffenmengsels voor mens en milieu te kunnen inschatten bij de vergunningverlening. Uitvoeringsinstanties, zoals omgevingsdiensten, kunnen deze methoden gebruiken. Het RIVM beveelt aan de voorstellen met uitvoeringsinstanties verder uit te werken, zodat ze in de praktijk goed zijn uit te voeren. Ook heeft het RIVM een methode ontwikkeld om in kaart te brengen waar in Nederland ZZS het meest voorkomen en/of effecten hebben op mens en milieu. Deze informatie kan bijvoorbeeld helpen bij het al dan niet toestaan van uitstoot in een gebied waar al veel schadelijke stoffen in het milieu zitten. Het RIVM benadrukt dat er nog onzekerheden zijn in deze methode en kaarten. Dat komt voor een groot deel door een gebrek aan gegevens over ZZS. Het RIVM werkt aan een database die meer gegevens over de uitstoot van ZZS door bedrijven op gaat leveren. Zo ontstaat naar verwachting een beter beeld van ZZS-mengsels in het milieu. In algemene zin benadrukt het RIVM om zo min mogelijk ZZS naar de leefomgeving uit te stoten. Dat verkleint de mogelijke cumulatieve effecten van ZZS voo, In the Netherlands, companies are required to obtain government permits that dictate the amount of chemicals, including Substances of Very High Concern (SVHCs; Dutch ZZS), they can emit. Typically, industrial companies emit mixtures of various substances simultaneously to water and air. However, permit issuers often assess risks on a persubstance basis rather than considering the entire mixture. People and the environment may be exposed to these mixtures. The risk that a mixture will have harmful effects (cumulation) could be higher than the probability of the constituent substances having harmful effects individually. The level of this risk depends on the mixture’s composition, the concentrations of the individual substances and the hazard posed by them. In a previous study, RIVM explored possibilities to better account for the effects of mixtures in the permitting process. These possibilities have now been developed further. Among other things, RIVM has devised methods to actually gauge the effects of substance mixtures on humans and the environment during the permit issuance process. Authorities, such as environmental services, can use these methods in their work. RIVM recommends working together with these authorities to refine the proposed methods for practical applicability. Furthermore, RIVM has created a method to map where SVHCs are most prevalent and/or where their effects on humans and the environment are most significant in the Netherlands. This information can aid decisions on permitting emissions in areas already burdened with significant environmental pollutants. RIVM emphasises that uncertainties still exist in these methods and maps, mainly due to a lack of data on SVHCs. RIVM is developing a database that is expected to provide more information on the emission of SVHCs by companies, which will lead to a better understanding of SVHC mixtures in the environment. In a general sense, RIVM stresses the importance of minimising the emission of SVHCs into

Published
2024

14. Normothermic machine perfusion of marginal grafts in high meld recipients: a NY center experience

Author

Todd, R., primary, Rosowicz, A., additional, Holzner, M., additional, Kressel, A., additional, Meyerovich, G., additional, Fagenson, A., additional, Hassan, A., additional, van Leeuwen, L., additional, Arvelakis, A., additional, DiNorcia, J., additional, Rocha, C., additional, Tabrizian, P., additional, Facciuto, M., additional, Schwartz, M., additional, Moon, J., additional, Schiano, T., additional, Kim- Schluger, L., additional, Akhtar, Z., additional, and Florman, S., additional

Published
2024
Full Text
View/download PDF

18. Targeted delivery of galunisertib using machine perfusion reduces fibrogenesis in an integrated ex vivo renal transplant and fibrogenesis model.

Author

van Leeuwen, L. Leonie, Ruigrok, Mitchel J. R., Kessler, Benedikt M., Leuvenink, Henri G. D., and Olinga, Peter

Subjects
*KIDNEY transplantation, *PERFUSION, *RENAL fibrosis, *KIDNEY physiology, *CELLULAR signal transduction, *MACHINERY
Abstract

Background and Purpose: Fibrosis in kidney allografts is a major post‐transplant complication that contributes to graft failure. Lately, multiple potent inhibitors of fibrosis‐related pathways have been developed such as galunisertib, an inhibitor of the transforming growth factor‐beta (TGF‐β/TGFβ1) signalling pathway. This drug, however, poses risks for adverse effects when administered systemically. Therefore, we devised a new repurposing strategy in which galunisertib is administered ex vivo. We combined machine perfusion and tissue slices to explore the antifibrotic effects of galunisertib in renal grafts. Experimental Approach: Porcine kidneys were subjected to 30 min of warm ischaemia, 24 h of oxygenated hypothermic machine perfusion and 6 h of normothermic machine perfusion with various treatments (i.e. untreated control, TGFβ1, galunisertib or TGFβ1 + galunisertib; n = 8 kidneys per group). To determine whether effects persisted upon ceasing treatment, kidney slices were prepared from respective kidneys and incubated for 48 h. Key Results: Galunisertib treatment improved general viability without negatively affecting renal function or elevating levels of injury markers or by‐products of oxidative stress during perfusion. Galunisertib also reduced inflammation and, more importantly, reduced the onset of fibrosis after 48 h of incubation. Conclusions and Implications: Our findings demonstrate the value of using machine perfusion for administering antifibrotic drugs such as galunisertib, proving it to be an effective example of repurposing. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Impact of Red Blood Cells on Function and Metabolism of Porcine Deceased Donor Kidneys During Normothermic Machine Perfusion

Author

Venema, Leonie H, van Leeuwen, L Leonie, Posma, Rene A, van Goor, Harry, Ploeg, Rutger J, Hannaert, Patrick, Hauet, Thierry, Minor, Thomas, Leuvenink, Henri G D, COPE Consortium, Groningen Institute for Organ Transplantation (GIOT), and Groningen Kidney Center (GKC)

Subjects
Erythrocytes, Swine, Medizin, Renal function, medicine.disease_cause, Kidney, DEXTRAN, Andrology, COLD-STORAGE, medicine, INJURY, Animals, REPERFUSION, PRESERVATION, Bovine serum albumin, Deceased donor, Machine perfusion, biology, Chemistry, TRANSPLANTATION, CONSUMPTION, Metabolism, Organ Preservation, Kidney Transplantation, COLLOIDS, Transplantation, Perfusion, biology.protein, DONATION, REABSORPTION, Oxidative stress, Biomarkers
Abstract

BackgroundNormothermic machine perfusion (NMP) protocols using blood-based solutions are commonly used in the assessment of kidneys before transplantation. This procedure is, nevertheless, limited by blood availability and warrants the search for alternatives. We compared a blood-based solution with a serum-like preservation solution (Aqix) enriched with colloids with and without red blood cells (RBCs).MethodsPorcine kidneys retrieved from an abattoir were subjected to 30 min of warm ischemia, followed by 3 h of hypothermic oxygenated machine perfusion at 4 °C. Subsequently, kidneys (n = 6 per group) were evaluated with NMP for 4 h with 5 different solutions: diluted blood, Aqix with BSA ± RBCs, or Aqix with dextran 40 ± RBCs.ResultsThroughout NMP, markers of renal function and tubular metabolism were favorable in groups with RBCs. The addition of RBCs resulted in 4- to 6-fold higher oxygen consumption rates. Controls had significantly higher ATP levels post-NMP, exhibited decreased production of oxidative stress markers, and had the highest creatinine clearance. In conclusion, this study shows that the addition of RBCs during NMP reduced renal injury, improved function, and was associated with increased renal metabolism.ConclusionsAlthough the RBC-BSA-supplemented Aqix solution was also able to support metabolism and renal function, a blood-based perfusion solution remains superior.

Published
2022

29. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19:an update from the Dutch Oncology COVID-19 Consortium

Author

de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Brocken, P., Drooger, J. C., de Groot, J. W.B., Stigt, J. A., Slingerland, M., Haberkorn, B. C.M., Aarts, M. J.B., Youssef, M., Faber, L. M., van de Wetering, R. A.W., Bard, M. P.L., Douma, G., Suijkerbuijk, K. P.M., Bakker, S. D., de Jong, W. K., Staal, A. J., Franken, B., de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Brocken, P., Drooger, J. C., de Groot, J. W.B., Stigt, J. A., Slingerland, M., Haberkorn, B. C.M., Aarts, M. J.B., Youssef, M., Faber, L. M., van de Wetering, R. A.W., Bard, M. P.L., Douma, G., Suijkerbuijk, K. P.M., Bakker, S. D., de Jong, W. K., Staal, A. J., and Franken, B.

Abstract

Aim of the study: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted cancer care. In this study, clinical patient characteristics related to COVID-19 outcomes and advanced care planning, in terms of non-oncological treatment restrictions (e.g. do-not-resuscitate codes), were studied in patients with cancer and COVID-19. Methods: The Dutch Oncology COVID-19 Consortium registry was launched in March 2020 in 45 hospitals in the Netherlands, primarily to identify risk factors of a severe COVID-19 outcome in patients with cancer. Here, an updated analysis of the registry was performed, and treatment restrictions (e.g. do-not-intubate codes) were studied in relation to COVID-19 outcomes in patients with cancer. Oncological treatment restrictions were not taken into account. Results: Between 27th March 2020 and 4th February 2021, 1360 patients with cancer and COVID-19 were registered. Follow-up data of 830 patients could be validated for this analysis. Overall, 230 of 830 (27.7%) patients died of COVID-19, and 60% of the remaining 600 patients with resolved COVID-19 were admitted to the hospital. Patients with haematological malignancies or lung cancer had a higher risk of a fatal outcome than other solid tumours. No correlation between anticancer therapies and the risk of a fatal COVID-19 outcome was found. In terms of end-of-life communication, 50% of all patients had restrictions regarding life-prolonging treatment (e.g. do-not-intubate codes). Most identified patients with treatment restrictions had risk factors associated with fatal COVID-19 outcome. Conclusion: There was no evidence of a negative impact of anticancer therapies on COVID-19 outcomes. Timely end-of-life communication as part of advanced care planning could save patients from prolonged suffering and decrease burden in intensive care units. Early discussion of treatment restrictions should therefore be part of routine oncological care, especially during the COVID-19 pandemic.

Published
2022

30. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Author

MS Medische Oncologie, Infection & Immunity, Cancer, Longziekten, de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Haanen, John B.A.G., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., Becker-Commissaris, A., Terheggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Strobbe, L., Koekkoek, J. A.F., Brocken, P., Drooger, J. C., de Groot, J. W.B., Aarts, M. J.B., Cirkel, G. A., Claessens, N. J.M., Jalving, M., Suijkerbuijk, K. P.M., van Lindert, A. S.R., Bakker, S. D., MS Medische Oncologie, Infection & Immunity, Cancer, Longziekten, de Joode, Karlijn, Tol, Jolien, Hamberg, Paul, Cloos, Marissa, Kastelijn, Elisabeth A., Borgers, Jessica S.W., Nuij, Veerle J.A.A., Klaver, Yarne, Herder, Gerarda J.M., Mutsaers, Pim G.N.J., Dumoulin, Daphne W., Oomen-de Hoop, Esther, van Diemen, Nico G.J., Libourel, Eduard J., Geraedts, Erica J., Bootsma, Gerben P., van der Leest, Cor H., Peerdeman, Anne L., Herbschleb, Karin H., Visser, Otto J., Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., de Vries, Elisabeth G.E., Hendriks, Lizza E.L., Beerepoot, Laurens V., Westgeest, Hans M., van den Berkmortel, Franchette W.P.J., Haanen, John B.A.G., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., Becker-Commissaris, A., Terheggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Strobbe, L., Koekkoek, J. A.F., Brocken, P., Drooger, J. C., de Groot, J. W.B., Aarts, M. J.B., Cirkel, G. A., Claessens, N. J.M., Jalving, M., Suijkerbuijk, K. P.M., van Lindert, A. S.R., and Bakker, S. D.

Published
2022

34. Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium

Author

de Joode, Karlijn, primary, Tol, Jolien, additional, Hamberg, Paul, additional, Cloos, Marissa, additional, Kastelijn, Elisabeth A., additional, Borgers, Jessica S.W., additional, Nuij, Veerle J.A.A., additional, Klaver, Yarne, additional, Herder, Gerarda J.M., additional, Mutsaers, Pim G.N.J., additional, Dumoulin, Daphne W., additional, Oomen-de Hoop, Esther, additional, van Diemen, Nico G.J., additional, Libourel, Eduard J., additional, Geraedts, Erica J., additional, Bootsma, Gerben P., additional, van der Leest, Cor H., additional, Peerdeman, Anne L., additional, Herbschleb, Karin H., additional, Visser, Otto J., additional, Bloemendal, Haiko J., additional, van Laarhoven, Hanneke W.M., additional, de Vries, Elisabeth G.E., additional, Hendriks, Lizza E.L., additional, Beerepoot, Laurens V., additional, Westgeest, Hans M., additional, van den Berkmortel, Franchette W.P.J., additional, Haanen, John B.A.G., additional, Dingemans, Anne-Marie C., additional, van der Veldt, Astrid A.M., additional, Becker-Commissaris, A., additional, Terheggen, F., additional, van den Borne, B.E.E.M., additional, van Warmerdam, L.J.C., additional, van Leeuwen, L., additional, van der Meer, F.S., additional, Tiemessen, M.A., additional, van Diepen, D.M., additional, Strobbe, L., additional, Koekkoek, J.A.F., additional, Brocken, P., additional, Drooger, J.C., additional, Heller, R., additional, de Groot, J.W.B., additional, Stigt, J.A., additional, Pitz, C.C.M., additional, Slingerland, M., additional, Borm, F.J., additional, Haberkorn, B.C.M., additional, van 't Westeinde, S.C., additional, Aarts, M.J.B., additional, van Putten, J.W.G., additional, Youssef, M., additional, Cirkel, G.A., additional, van Rooijen, C.R., additional, Citgez, E., additional, Barlo, N.P., additional, Scholtes, B.M.J., additional, Koornstra, R.H.T., additional, Claessens, N.J.M., additional, Faber, L.M., additional, Rikers, C.H., additional, van de Wetering, R.A.W., additional, Veurink, G.L., additional, Bouter, B.W., additional, Houtenbos, I., additional, Bard, M.P.L., additional, Douma, G., additional, Jalving, M., additional, Hiltermann, T.J.N., additional, Schuurbiers-Siebers, O.C.J., additional, Suijkerbuijk, K.P.M., additional, van Lindert, A.S.R., additional, van de Wouw, A.J., additional, van den Boogaart, V.E.M., additional, Bakker, S.D., additional, Looysen, E., additional, de Jong, W.K., additional, Siemerink, E.J.M., additional, Staal, A.J., additional, Franken, B., additional, and van Geffen, W.H., additional

Published
2022
Full Text
View/download PDF

38. Investigation of the air quality around the landfill Sint Maarten 2019 : Measurements and results of the MOD field visit in January 2019

Author

Morgenstern, P, van Putten, E, Stolk, A, and van Leeuwen, L

Subjects
luchtkwaliteit, geurhinder, irma, landfill, afval, RIVM report 2019-0056, air quality, afvalberg, brand, odour, waste, Sint Maarten, MOD, fire
Abstract

At the beginning of 2019, the RIVM measured the air quality around the landfill at Philipsburg, Sint Maarten for two weeks. No or hardly any harmful substances were measured. During the measurement period there were no open fires at the landfill. As a result, the RIVM is unable to assess the potential health risks of substances released in the event of an open fire at the landfill. In order to do so, it is necessary to take measurements during an open fire. The local fire department could perform this task. RIVM can support the fire brigade with specialized equipment and knowledge. The measurements were taken by the Environmental Incident Service (MOD) of the National Institute for Public Health and the Environment (RIVM) between 24th January and 6th February 2019. The measurements were taken at a distance of 500 to 2500 metres from the landfill. The RIVM did not perform any measurements at the landfill itself. The locations were chosen to provide a good insight into the possible exposure of the local population. Measurements were taken to identify the following substances: particulate matter (PM10), inorganic gases, Volatile Organic Components (VOC), aldehydes, Polycyclic Aromatic Hydrocarbons (PAHs), dioxins and Polychlorinated Biphenyls (PCB). This is a broad "package" of substances that might be relevant in case of a fire. From the 206 samples taken, a representative selection of 90 samples was analyzed in special laboratories. In some cases, the concentrations of aluminum and possibly of chromium measured were found to exceed the standards that apply if people were to breathe these substances continuously throughout their lives. However, the health effects of these exceedances are negligible. For PAHs, some samples exceeded the standards that would apply if these substances were ingested daily during a lifetime. This results in an almost negligible health risk. The odour nuisance that people experience can cause health problems such as nausea and headache.

Published
2020

39. Proteomic analysis of machine perfusion solution from brain dead donor kidneys reveals that elevated complement, cytoskeleton and lipid metabolism proteins are associated with 1-year outcome

Author

MS Nefrologie, Circulatory Health, van Leeuwen, L. Leonie, Spraakman, Nora A., Brat, Aukje, Huang, Honglei, Thorne, Adam M., Bonham, Sarah, van Balkom, Bas W.M., Ploeg, Rutger J., Kessler, Benedikt M., Leuvenink, Henri G.D., MS Nefrologie, Circulatory Health, van Leeuwen, L. Leonie, Spraakman, Nora A., Brat, Aukje, Huang, Honglei, Thorne, Adam M., Bonham, Sarah, van Balkom, Bas W.M., Ploeg, Rutger J., Kessler, Benedikt M., and Leuvenink, Henri G.D.

Published
2021

41. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

de Joode, Karlijn, primary, Dumoulin, Daphne W., additional, Tol, Jolien, additional, Westgeest, Hans M., additional, Beerepoot, Laurens V., additional, van den Berkmortel, Franchette W.P.J., additional, Mutsaers, Pim G.N.J., additional, van Diemen, Nico G.J., additional, Visser, Otto J., additional, Oomen-de Hoop, Esther, additional, Bloemendal, Haiko J., additional, van Laarhoven, Hanneke W.M., additional, Hendriks, Lizza E.L., additional, Haanen, John B.A.G., additional, de Vries, Elisabeth G.E., additional, Dingemans, Anne-Marie C., additional, van der Veldt, Astrid A.M., additional, van Loenhout, C.J., additional, van der Leest, C.H., additional, Becker-Commissaris, A., additional, Borgers, J.S.W., additional, Terhegggen, F., additional, van den Borne, B.E.E.M., additional, van Warmerdam, L.J.C., additional, van Leeuwen, L., additional, van der Meer, F.S., additional, Tiemessen, M.A., additional, van Diepen, D.M., additional, Klaver, Y., additional, Hamberg, A.P., additional, Libourel, E.J., additional, Strobbe, L., additional, Cloos, M., additional, Geraedts, E.J., additional, Drooger, J.C., additional, Heller, R., additional, de Groot, J.W.B., additional, Stigt, J.A., additional, Nuij, V.J.A.A., additional, Pitz, C.C.M., additional, Slingerland, M., additional, Borm, F.J., additional, Haberkorn, B.C.M., additional, Westeinde, S.C. van 't, additional, Aarts, M.J.B., additional, van Putten, J.W.G., additional, Youssef, M., additional, Cirkel, G.A., additional, Herder, G.J.M., additional, van Rooijen, C.R., additional, Citgez, E., additional, Barlo, N.P., additional, Scholtes, B.M.J., additional, Koornstra, R.H.T., additional, Claessens, N.J.M., additional, Faber, L.M., additional, Rikers, C.H., additional, van de Wetering, R.A.W., additional, Veurink, G.L., additional, Bouter, B.W., additional, Houtenbos, I., additional, Bard, M.P.L., additional, Herbschleb, K.H., additional, Kastelijn, E.A., additional, Brocken, P., additional, Douma, G., additional, Jalving, M., additional, Hiltermann, T.J.N., additional, Schuurbiers-Siebers, O.C.J., additional, Suijkerbuijk, K.P.M., additional, van Lindert, A.S.R., additional, van de Wouw, A.J., additional, van den Boogaart, V.E.M., additional, Bakker, S.D., additional, Looysen, E., additional, Peerdeman, A.L., additional, de Jong, W.K., additional, Siemerink, E.J.M., additional, Staal, A.J., additional, Franken, B., additional, van Geffen, W.H., additional, and Bootsma, G.P., additional

Published
2020
Full Text
View/download PDF

45. Book reviews

Author

Kuipers, S. K., Visser, H., van der Lecq, Fieke, Berk, Jan Marc, Keuzenkamp, Hugo A., Fase, M. M. G., Swank, Otto, Hoen, Herman, van Selm, Bert, Furth, Dave, Kooreman, Peter, ten Cate, Arie, de Grip, Andries, and van Leeuwen, L.

Published
1996
Full Text
View/download PDF

48. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

de Joode, K., Dumoulin, D.W., Tol, J., Westgeest, H.M. (Hans), Beerepoot, L.V. (Laurens), van den Berkmortel, F.W.P., Mutsaers, P.G.N.J. (Pim), van Diemen, N.G.J., Visser, O.J., Oomen-de Hoop, E., Bloemendal, H.J. (Haiko), van Laarhoven, HW, Hendriks, L.E.L., Haanen, J.B. (John), de Vries, E.G., Dingemans, A.M.A., van der Veldt, A.A.M., Loenhout, C.J. (Keetie) van, van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, BE, van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P. (Paul), Libourel, E.J. (Eduard), Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C. (Jan), Heller, R., de Groot, J.W.H., Stigt, JA, Nuij, V.J.A.A. (Veerle), Pitz, C.C.M., Slingerland, M. (Marije), Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C.V., Aarts, M.J.B. (Maureen), van Putten, J.W.G., Youssef, M., Cirkel, G.A. (Geert), Herder, G.J., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H., Claessens, N.J.M., Faber, LM, Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H. (Karin), Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M. (Karin), van Lindert, A.S.R., de Wouw, A.J.V., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., Bootsma, G.P. (G.), de Joode, K., Dumoulin, D.W., Tol, J., Westgeest, H.M. (Hans), Beerepoot, L.V. (Laurens), van den Berkmortel, F.W.P., Mutsaers, P.G.N.J. (Pim), van Diemen, N.G.J., Visser, O.J., Oomen-de Hoop, E., Bloemendal, H.J. (Haiko), van Laarhoven, HW, Hendriks, L.E.L., Haanen, J.B. (John), de Vries, E.G., Dingemans, A.M.A., van der Veldt, A.A.M., Loenhout, C.J. (Keetie) van, van der Leest, C.H., Becker-Commissaris, A., Borgers, J.S.W., Terhegggen, F., van den Borne, BE, van Warmerdam, L.J.C., van Leeuwen, L., van der Meer, F.S., Tiemessen, M.A., van Diepen, D.M., Klaver, Y., Hamberg, A.P. (Paul), Libourel, E.J. (Eduard), Strobbe, L., Cloos, M., Geraedts, E.J., Drooger, J.C. (Jan), Heller, R., de Groot, J.W.H., Stigt, JA, Nuij, V.J.A.A. (Veerle), Pitz, C.C.M., Slingerland, M. (Marije), Borm, F.J., Haberkorn, B.C.M., Westeinde, S.C.V., Aarts, M.J.B. (Maureen), van Putten, J.W.G., Youssef, M., Cirkel, G.A. (Geert), Herder, G.J., van Rooijen, C.R., Citgez, E., Barlo, N.P., Scholtes, B.M.J., Koornstra, R.H., Claessens, N.J.M., Faber, LM, Rikers, C.H., van de Wetering, R.A.W., Veurink, G.L., Bouter, B.W., Houtenbos, I., Bard, M.P.L., Herbschleb, K.H. (Karin), Kastelijn, E.A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T.J.N., Schuurbiers-Siebers, O.C.J., Suijkerbuijk, K.P.M. (Karin), van Lindert, A.S.R., de Wouw, A.J.V., van den Boogaart, V.E.M., Bakker, S.D., Looysen, E., Peerdeman, A.L., de Jong, W.K., Siemerink, E.J.M., Staal, A.J., Franken, B., van Geffen, W.H., and Bootsma, G.P. (G.)

Abstract

Aim of the study: Patients with cancer might have an increased risk for severe outcome of coronavirus disease 2019 (COVID-19). To identify risk factors associated with a worse outcome of COVID-19, a nationwide registry was developed for patients with cancer and COVID-19. Methods: This observational cohort study has been designed as a quality of care registry and is executed by the Dutch Oncology COVID-19 Consortium (DOCC), a nationwide collaboration of oncology physicians in the Netherlands. A questionnaire has been developed to collect pseudonymised patient data on patients’ characteristics, cancer diagnosis and treatment. All patients with COVID-19 and a cancer diagnosis or treatment in the past 5 years are eligible. Results: Between March 27th and May 4th, 442 patients were registered. For this first analysis, 351 patients were included of whom 114 patients died. In multivariable analyses, age 65 years (p < 0.001), male gender (p Z 0.035), prior or other malignancy (p Z 0.045) and active diagnosis of haematological malignancy (p Z 0.046) or lung cancer (p Z 0.003) were independent risk factors for a fatal outcome of COVID-19. In a subgroup analysis of patients with active malignancy, the risk for a fatal outcome was mainly determined by tumour type (haematological malignancy or lung cancer) and age (65 years). Conclusion: The findings in this registry indicate that patients with a haematological malignancy or lung cancer have an increased risk of a worse outcome of COVID-19. During the ongoing COVID-19 pandemic, these vulnerable patients should avoid exposure to severe acute respiratory syndrome coronavirus 2, whereas treatment adjustments and prioritising vaccination, when available, should also be considered

Published
2020
Full Text
View/download PDF

49. Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study

Author

MS Medische Oncologie, Cancer, Infection & Immunity, Longziekten, de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Loenhout, C. J., van der Leest, C. H., Becker-Commissaris, A., Borgers, J. S.W., Terhegggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Klaver, Y., Hamberg, A. P., Libourel, E. J., Strobbe, L., Cloos, M., Geraedts, E. J., Drooger, J. C., Heller, R., de Groot, J. W.B., Stigt, J. A., Nuij, V. J.A.A., Pitz, C. C.M., Slingerland, M., Borm, F. J., Haberkorn, B. C.M., Westeinde, S. C.van t., Aarts, M. J.B., van Putten, J. W.G., Youssef, M., Cirkel, G. A., Herder, G. J.M., van Rooijen, C. R., Citgez, E., Barlo, N. P., Scholtes, B. M.J., Koornstra, R. H.T., Claessens, N. J.M., Faber, L. M., Rikers, C. H., van de Wetering, R. A.W., Veurink, G. L., Bouter, B. W., Houtenbos, I., Bard, M. P.L., Herbschleb, K. H., Kastelijn, E. A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T. J.N., Schuurbiers-Siebers, O. C.J., Suijkerbuijk, K. P.M., van Lindert, A. S.R., van de Wouw, A. J., van den Boogaart, V. E.M., Bakker, S. D., Looysen, E., Peerdeman, A. L., de Jong, W. K., Siemerink, E. J.M., Staal, A. J., Franken, B., van Geffen, W. H., Bootsma, G. P., MS Medische Oncologie, Cancer, Infection & Immunity, Longziekten, de Joode, Karlijn, Dumoulin, Daphne W., Tol, Jolien, Westgeest, Hans M., Beerepoot, Laurens V., van den Berkmortel, Franchette W.P.J., Mutsaers, Pim G.N.J., van Diemen, Nico G.J., Visser, Otto J., Oomen-de Hoop, Esther, Bloemendal, Haiko J., van Laarhoven, Hanneke W.M., Hendriks, Lizza E.L., Haanen, John B.A.G., de Vries, Elisabeth G.E., Dingemans, Anne Marie C., van der Veldt, Astrid A.M., van Loenhout, C. J., van der Leest, C. H., Becker-Commissaris, A., Borgers, J. S.W., Terhegggen, F., van den Borne, B. E.E.M., van Warmerdam, L. J.C., van Leeuwen, L., van der Meer, F. S., Tiemessen, M. A., van Diepen, D. M., Klaver, Y., Hamberg, A. P., Libourel, E. J., Strobbe, L., Cloos, M., Geraedts, E. J., Drooger, J. C., Heller, R., de Groot, J. W.B., Stigt, J. A., Nuij, V. J.A.A., Pitz, C. C.M., Slingerland, M., Borm, F. J., Haberkorn, B. C.M., Westeinde, S. C.van t., Aarts, M. J.B., van Putten, J. W.G., Youssef, M., Cirkel, G. A., Herder, G. J.M., van Rooijen, C. R., Citgez, E., Barlo, N. P., Scholtes, B. M.J., Koornstra, R. H.T., Claessens, N. J.M., Faber, L. M., Rikers, C. H., van de Wetering, R. A.W., Veurink, G. L., Bouter, B. W., Houtenbos, I., Bard, M. P.L., Herbschleb, K. H., Kastelijn, E. A., Brocken, P., Douma, G., Jalving, M., Hiltermann, T. J.N., Schuurbiers-Siebers, O. C.J., Suijkerbuijk, K. P.M., van Lindert, A. S.R., van de Wouw, A. J., van den Boogaart, V. E.M., Bakker, S. D., Looysen, E., Peerdeman, A. L., de Jong, W. K., Siemerink, E. J.M., Staal, A. J., Franken, B., van Geffen, W. H., and Bootsma, G. P.

Published
2020

50. The additive value of restaging-CT during neoadjuvant chemotherapy for gastric cancer

Author

Arts Assistenten CTC, MS CGO, Cancer, MS Radiologie, Divisie Beeld & Oncologie, Gertsen, E. C., de Jongh, C., Brenkman, H. J.F., Mertens, A. C., Broeders, I. A.M.J., Los, M., Boerma, D., ten Bokkel Huinink, D., van Leeuwen, L., Wessels, F. J., van Hillegersberg, R., Ruurda, J. P., Arts Assistenten CTC, MS CGO, Cancer, MS Radiologie, Divisie Beeld & Oncologie, Gertsen, E. C., de Jongh, C., Brenkman, H. J.F., Mertens, A. C., Broeders, I. A.M.J., Los, M., Boerma, D., ten Bokkel Huinink, D., van Leeuwen, L., Wessels, F. J., van Hillegersberg, R., and Ruurda, J. P.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results